Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit. CEO Troy Wilson will present in a fireside chat on May 20, 2021, at 10:20 a.m. PT. A live audio webcast will be available on the company's website, with a replay following the event. Kura's pipeline includes KO-539, a menin inhibitor in a Phase 1/2 trial, and Tipifarnib, a farnesyl transferase inhibitor with Breakthrough Therapy Designation, currently in a registration-directed study for head and neck cancer.

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2^nd Annual Virtual Oncology Innovation Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat on Thursday, May 20, 2021 at 10:20 a.m. PT / 1:20 p.m. ET.

A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. Kura is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What is Kura Oncology's role in the Cowen Virtual Oncology Innovation Summit?

Kura Oncology will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit, with CEO Troy Wilson presenting a virtual fireside chat on May 20, 2021.

When is Kura Oncology's presentation at the Cowen Summit?

Kura Oncology's presentation is scheduled for May 20, 2021, at 10:20 a.m. PT / 1:20 p.m. ET.

Where can I access the live webcast of Kura Oncology's presentation?

The live audio webcast of Kura Oncology's presentation will be available in the Investors section of their website.

What drugs are currently in Kura Oncology's pipeline?

Kura Oncology's pipeline includes KO-539, targeting relapsed acute myeloid leukemia, and Tipifarnib, for HRAS mutant head and neck squamous cell carcinoma.

What is the significance of Tipifarnib in Kura Oncology's research?

Tipifarnib has received Breakthrough Therapy Designation for treating patients with HRAS mutant head and neck squamous cell carcinoma and is in a registration-directed study.